Biphasic or Mixed
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo
Journal of Translational Medicine 2022 June 25 [Link] Roberto Bei, Monica Benvenuto, Chiara Focaccetti, Sara Fazi, Marta Moretti, Daniela Nardozi, Valentina Angiolini, Sara Ciuffa, Loredana Cifaldi, Raffaele Carrano, Camilla Palumbo, Martino Tony Miele, Riccardo Bei, Giovanni Barillari, Vittorio Manzari, Enrico De Smaele, Andrea Modesti, Laura Masuelli Abstract Malignant mesothelioma (MM) is a rare orphan aggressive…
Read MoreBAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma
International Journal of Gynecological Pathology 2022 March 29 [Link] Kyle M Devins, Lawrence Zukerberg, Jaclyn C Watkins, Yin Pun Hung, Esther Oliva Abstract Peritoneal mesothelioma (PM) and serous neoplasms can be difficult to differentiate, particularly in small biopsies. BRCA1-associated protein 1 (BAP1) is expressed in benign tissues, but over 50% of PMs demonstrate complete loss…
Read MoreDissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications
Frontiers in Medicine 2022 April 13 [Link] Marcelo Luiz Balancin, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Cecília Farhat, Aline Kawassaki Assato, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Alexandre Muxfeldt Ab’Saber, Teresa Yae Takagaki, Vera Luiza Capelozzi Abstract Background: Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM…
Read MoreExpression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study
The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…
Read MoreMicro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…
Read MorePrognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients
Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters. Methods:…
Read MorePrognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients
Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters. Methods:…
Read MoreUsefulness of Cyclin D1/Podoplanin Dual Immunohistochemical Stain to Differentiate Malignant Mesothelioma From Reactive Mesothelial Proliferations
American Journal of Clinical Pathology 2022 March 14 [Link] Raghavendra Pillappa, Austin Wiles, Sadia Sayeed, Valentina Robila Abstract Objectives: To examine the potential of cyclin D1/podoplanin dual immunohistochemical stain to differentiate malignant mesothelioma from reactive mesothelial proliferations. Methods: Cyclin D1/podoplanin dual immunohistochemistry was performed on 34 surgical cases of reactive mesothelial proliferations, malignant mesothelioma, and…
Read MoreImaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group
Lung Cancer 2022 February [Link] Samuel G Armato, Anna K Nowak, Roslyn J Francis, Sharyn I Katz, Manizha Kholmatov, Kevin G Blyth, Eyjolfur Gudmundsson, Andrew C Kidd, Ritu R Gill Abstract Imaging of mesothelioma plays a role in all aspects of patient management, including disease detection, staging, evaluation of treatment options, response assessment, pre-surgical evaluation,…
Read MoreEpigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
Epigenomes 2021 December 14 [Link] Maria Fortunata Lofiego, Sara Cannito, Carolina Fazio, Francesca Piazzini, Ornella Cutaia, Laura Solmonese, Francesco Marzani, Carla Chiarucci, Anna Maria Di Giacomo, Luana Calabrò, Sandra Coral, Michele Maio, Alessia Covre Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a severe prognosis, and with a long-standing need for more effective…
Read More